General:

1. R.M. Sharkey, D.M. Goldenberg. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv Rev. 60(12): 1407-20, 2008.
2. D.M. Goldenberg. Radiolabelled monoclonal antibodies in the treatment of metastatic cancer. Curr Oncol. 14(1): 39-42, 2007.
3. D.M. Goldenberg, R.M. Sharkey. Novel radiolabeled antibody conjugates. Oncogene 26(25): 3734-44, 2007.
4. D.M. Goldenberg, R.M. Sharkey. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50(4): 248-64, 2006.
5. R.M. Sharkey, D.M. Goldenberg. Targeted therapy of cancer: a new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 56(4): 226-43, 2006.

Epratuzumab:

1 E.A. Raetz, M.S. Cairo, M.J. Borowitz, S.M. Blaney, M.D. Krailo, T.A. Leil, J.M. Reid, D.M. Goldenberg, W.A. Wegener, W.L. Carroll, P.C. Adamson. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children’s Oncology Group pilot study. J Clin Oncol. 26(22): 3756-62, 2008.
2 F. Kraeber-Bodere, F. Morschhauser, D. Huglo, M. Petillon, J. Chatal, J.L. Harousseau, H. Horne, N. Teoh, W.A. Wegener, D.M. Goldenberg. Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: results at high cumulative doses of 90Y. Proc. 2008 Amer. Soc. Clin. Onc. 44th Annual Meeting, J. Clin. Oncol. 26(15S): 454s (Abstr. #8502), 2008.
3 C. Bodet-Milin, M. Cherel, A. Faivre-Chauvet, M. Bardies, S. Le Gouill, T. Gastinne, J-F. Chatal, D.M. Goldenberg, F. Kraeber-Bodere. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Cancer Ther 6: 247-56, 2008.
4 C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.L. Harousseau, W.A. Wegener, D.M. Goldenberg, D. Huglo. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica. 93(2): 390-7, 2008.
5 T. Dorner, D.M. Goldenberg. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Management 3(5): 953-959, 2007.
6 A.M. Jacobi, D.M. Goldenberg, F.T. Hiepe, A. Radbruch, G.R. Burmester, T. Dorner. Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann Rheum Dis. Aug. 2, 2007.
7 J.P. Leonard, D.M. Goldenberg. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26(25): 3704-13, 2007.
8 D.M. Goldenberg. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 6(10): 1341-53, 2006.

Veltuzumab:

1. D.M. Goldenberg, C. Chang, E.A. Rossi, T.M. Cardillo, W.A. Wegener, N. Teoh, J.P. Leonard, L.E. Fayad, B. Coiffier, F. Morchhauser. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. Proc. 2008 Amer. Soc. Clin. Onc. 44th Annual Meeting, J. Clin. Oncol. 26(15S): 142s (Abstr. #3043), 2008.
2. F. Morschhauser, J.P. Leonard, L Fayad, B. Coiffier, M. Petillon, M. Coleman, H. Horne, N. Teoh, W.A. Wegener, D.M. Goldenberg. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20) in refractory or recurrent NHL: Phase I/II results. J Clin Oncol. 25(18S): 449s (Abstr.# 8032), 2007.
3. F. Morschhauser, J.P. Leonard, L. Fayad, B. Coiffier, S.J. Schuster, M.J.S. Dyer, M.-O. Petillon, M. Coleman, A. Bahkti. H. Horne, L. Xu, N. Teoh, W.A. Wegener, D.M. Goldenberg. Rituximab-relapsing patients with non-Hodgkin’s lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20): Phase I/II results. Blood 108(11): 769a (Abstr.# 2719), 2006.
4. F. Morschhauser, J.P. Leonard, B. Coiffier, M. Petillon, M. Coleman, A. Bahkti, N. Teoh, W.A. Wegener, D.M. Goldenberg. Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20) in NHL. J Clin Oncol. 24(18S): 429s (Abstr.# 7530), 2006.

Epratuzumab – Rituximab combination:

1. M. Mattes, R.M. Sharkey, H. Karacay, D.M. Goldenberg. Therapy of B-lymphoma xenografts with a combination of unconjugated anti-CD20 and 90-Y-anti-CD22 antibodies. Proc. Soc. Nucl. Med. 55th Annual Meeting, J. Nucl. Med. 49(Suppl 1): 109P (Abstr. #432), 2008.
2. I. N. Micallef, M. J. Maurer, D. A. Nikcevich, M. Cannon, D. F. Moore, P. Kurtin, T. E. Witzig. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Proc. 2008 Amer. Soc. Clin. Onc. 44th Annual Meeting, J Clin Oncol 26(15S): 454s (Abstr #8500), 2008.
3. J.P. Leonard, S.J. Schuster, C. Emmanouilides, F. Couture, N. Teoh, W.A. Wegener, D.M. Goldenberg. Durable complete responses following therapy with epratuzumab plus rituximab: Final efficacy results of a multicenter study in recurrent indolent non-Hodgkin’s lymphoma (NHL). Blood 110(11): 1002a (Abstr.# 3419), 2007.
4. S.J. Strauss, F. Morschhauser, J. Rech, R. Repp, P. Solal-Celigny, P.L. Zinzani, A. Engert, B. Coiffier, D.F. Hoelzer, W.A. Wegener, N.K. Teoh, D.M. Goldenberg, T.A Lister. Multicenter Phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. 24(24): 3880-6, 2006.
5. I.N.M. Micallef, B.S. Kahl, M.J. Maurer, A. Dogan, S.M. Ansell, J.P. Colgan, S. Geyer, D.J. Inwards, W.L. White, T.M. Habermann. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107(12): 2826-32, 2006.

PAM4:

1. D.V. Gold, Z. Karanjawala, D.E. Modrak, D.M. Goldenberg, R.H. Hruban. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 13(24): 7380-7, 2007.
2. S.A. Gulec, K. Pennington, D. Bruetman, S. Garl, H. Horne, D. Gold, W.Wegener, D.M. Goldenberg. A phase-I study of 90Y-hPAM4 (humanized anti-MUC1 monoclonal antibody) in patients with unresectable and metastatic pancreatic cancer. J Nucl Med. 48(Supple 2): 393P (Abstr.# 1664), 2007.
3. S.A. Gulec, S.J. Cohen, L.S. Zuckier, H. Horne, N. Teoh, W.A. Wegener, D.V. Gold, D.M. Goldenberg. First clinical experience with 90Y-radiolabeled humanized anti-MUC1 antibody (hPAM4) in patients with advanced pancreatic cancer: A phase I study. J Clin Oncol. 25(18S): 636s (Abstr.# 15034), 2007.
4. D.V. Gold, D.E. Modrak, Z. Ying, T.M. Cardillo, R.M. Sharkey, D.M. Goldenberg. New MUC1 serum immunoassay differentiates for pancreatic cancer from pancreatitis. J Clin Oncol. 24(2): 252-58, 2006.

Milatuzumab:

1. R. Stein, D.M. Goldenberg. Combining milatuzumab (anti-CD74 humanized mAb) and bortezomib or lenalidomide yields improved therapy of multiple myeloma in pre-clinical studies. Proc. Amer. Assoc. Cancer Res. Annual Meeting, 49: 956 (Abstr. #4024), 2008.
2. R. Stein, D.M. Goldenberg. Therapeutic effects of the anti-CD74 mAb, milatuzumab, compared to anti-CD20 antibodies, in B-cell lymphomas. Proc AACR Molecular Targets and Cancer Therapeutics, 83-84 (Abstr.# A58), 2007.
3. R. Stein, M.J. Mattes, T.M. Cardillo, H.J. Hansen, C.H. Chang, J. Burton, S. Govindan, D.M. Goldenberg. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 13(18 Pt 2): 5556s-5563s, 2007.
4. I. Binsky, M. Haran, D. Starlets, Y. Gore, F. Lantner, N. Harpaz, L. Leng, D.M. Goldenberg, L. Shvidel, A. Berrebi, R. Bucala, I. Shachar. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic Lymphocytic leukemia survival. Proc Natl Acad Sci USA. 104(33): 13408-13, 2007.

Labetuzumab

1. T. Liersch, J. Meller, C. Sahlmann, M. Ghadimi, H. Becker, D.M. Goldenberg. Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM). Proc. 2008 Amer. Soc. Clin. Onc. 44th Annual Meeting, J. Clin. Oncol. 26(15S): 198s (Abstr. #4080), 2008.
2. T. Liersch, J. Meller, M. Bittrich, B. Kulle, H. Becker, D.M. Goldenberg. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 14(9): 2577-90, 2007.
3. M. Meller, T. Liersch, C. O. Sahlmann, M. Niessner, M. Ghadimi, W.A. Wegener, H. Becker, D.M. Goldenberg. Safety and efficacy of repeated anti-CEA radioimmunotherapy (RAIT) with 131I-Labetuzumab post salvage resection of colorectal liver metastases (CLM). J Nucl Med 48(Suppl 2): 38P (Abstr.# 129), 2007.
4. T. Liersch, J. Meller, T. Lorf, C. Sahlmann, M. Niessner, C. Langer, B.M. Ghadimi, W.A. Wegener, H. Becker, D.M. Goldenberg. Safety and efficacy of repeated anti-CEA radioimmunotherapy (RAIT) with 131I-labetuzumab post salvage resection of colorectal liver metastases. J Clin Oncol. 25(18S): 625s (Abstr.# 14507), 2007.
5. R.D. Blumenthal, E. Leon, H.J. Hansen, D.M. Goldenberg. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 7:2, 2007.
6. T. Liersch, H. Becker, D.M. Goldenberg. Improved survival after resection of colorectal liver metastases: in reply. J Clin Oncol. 24(17): 2680-2681, 2006.
7. G. Hajjar, R.M. Sharkey, J. Burton, C.H. Zhang, D. Yeldell, A. Matthies, A. Alavi, M.J. Losman, A. Brenner, D.M. Goldenberg. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2(1): 31-42, 2002.

Dock-and-Lock Method:

1. C.-H. Chang, E. Rossi, M. Loo, D. Nordstrom, E. Chan, T. Cardillo, D. M. Goldenberg. A modular method to prepare novel tetrameric cytokines, IFN, G-CSF, and EOP, with improved pharmacokinetics by the dock-and-lock (DNL) platform technology. Proc. Amer. Assoc. Cancer Res. Annual Meeting, 49: 1168 (Abstr. #4906), 2008.
2. D.M. Goldenberg, E.A. Rossi, R.M. Sharkey, W.J. McBride, C.H. Chang. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 49(1): 158-63, 2008.
3. E.A. Rossi, W.J. McBride, D.L. Nordstrom, P.Trisal, T.M. Cardillo, D.M. Goldenberg, C.H. Chang. A new class of dimeric α-interferons (IFN-α) made by the Dock and Lock (DNL) method for improved cancer therapy. Blood 110(11): 419a (Abstr.# 1396), 2007.
4. C.H. Chang, E.A. Rossi, D.M. Goldenberg. The Dock and Lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res. 13(18 Pt 2): 5586s-5591s, 2007.
5. E.A. Rossi, D.M. Goldenberg, T.M. Cardillo, W.J. McBride, R.M. Sharkey, C.H. Chang. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 103 (18): 6841-6, 2006.

Bispecific Antibody:

1. Z. Qu, D.M. Goldenberg, T.M. Cardillo, V. Shi, H.J. Hansen, C.-H. Chang. Bispecifric anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood. 111(4): 2211-9, 2008
2. Z. Qu, T.M. Cardillo, V. Shi, D.L. Delaney, H.J. Hansen, C.-H. Chang, D.M. Goldenberg. Recombinant bispecific monoclonal antibody (bsMAb) against CD20 and CD22 active in vitro and in vivo against B-cell lymphomas. Blood 108(11): 713a (Abstr.# 2521), 2006.
3. E.A. Rossi, M.J. Losman, D.L. Nordstrom, T. Cardillo, M. Loo, J. Kopinski, Z. Qu, D.M. Goldenberg. Multivalent anti-CD20/anti-CD22 bispecific antibody fusion proteins made by the DNL method show potent lymphoma cytotoxicity. Blood 108(11): 707a (Abstr.# 2495), 2006.
4. Z. Qu, V. Shi, D.L. Delaney, H.J. Hansen, C.-H. Chang, D.M. Goldenberg. Anti-lymphoma effects of recombinant bispecific monoclonal antibodies (bsMAbs) against CD20 and CD22 antigens. Proc. Eleventh Conf. on Cancer Therapy, Cancer Biotherapy & Radiopharmaceuticals, 21(4): 403 (Abstr.# 61), 2006.

Pretargeting:

1 F. Aarts, O.C. Boerman, R.M. Sharkey, T. Hendriks, C. Chang, W.J. McBride, R. Bleichrodt, W.J. Oyen, D.M. Goldenberg. Radioimmunoscintigraphy of colorectal cancer using a two-step pretargeting method.. Proc. Soc. Nucl. Med. 55th Annual Meeting, J. Nucl. Med. 49(Suppl 1): 335P (Abstr. #1420), 2008.
2 R. M. Sharkey, H. Karacay, E.A. Rossi, C. Chang, W.J. McBride, D.M. Goldenberg. Pretargeted radioimmunotherapy of pancreatic cancer with a recombinant tri-Fab bispecific antibody and a 90Y-hapten-peptide. Proc. Soc. Nucl. Med. 55th Annual Meeting, J. Nucl. Med. 49(Suppl 1): 313P (Abstr. #1331), 2008.
3 O.C. Boerman, R.M. Sharkey, G. Franssen, C. Chang, E.A. Rossi, W.J. McBride, R. Schoffelen, W. van der Graff, W.J. Oyen, D.M. Goldenberg. Pretargeted immunoPET imaging of CEA-expressing tumors using a Ga-68 labeled peptide. Proc. Soc. Nucl. Med. 55th Annual Meeting, J. Nucl. Med. 49(Suppl 1): 52P (Abstr. #209), 2008.
4 R.M. Sharkey, H. Karacay, S. Litwin, E.A. Rossi, W.J. McBride, C.-H. Chang, D.M. Goldenberg. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin’s lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 68(13): 5282-90, 2008.
5 D.V. Gold, D.M. Goldenberg, H. Karacay, E.A. Rossi, C.-H. Chang, T.M. Cardillo, W.J. McBride, R.M. Sharkey. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 68(12): 4819-26, 2008.
6 R.M. Sharkey, H. Karacay, S. Vallabhajosula, W.J. McBride, E.A. Rossi, C.-H. Chang, S.J. Goldsmith, D.M. Goldenberg. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 246(2): 497-507, 2008.
7 H. Karacay, R.M. Sharkey, E.A. Rossi, C. Chang, W.J. McBride, D.M. Goldenberg. Pretargeting B-cell lymphoma with recombinant bispecific antibodies. J Nucl Med. 48(Suppl 2): 341P (Abstr.# 1479), 2007.
8 P.Y. Brard, H. Karacay, R. Stein, R.M. Sharkey, M.J. Mattes, C.-H. Chang, E.A. Rossi, W.J. McBride, D.M. Goldenberg. A divalent hapten-peptide induces apoptosis in human non-Hodgkin lymphoma cell lines targeted by anti-CD20 x anti-hapten bispecific antibodies. Clin Cancer Res. 13(18): 5564s-71s, 2007.
9 D.M. Goldenberg, J.-F. Chatal, J. Barbet, O. Boerman, R.M. Sharkey. Cancer imaging and therapy with bispecific antibody pretargeting. Update on Cancer Therapeutics. 2: 19-31, 2007.
10 J.F. Chatal, L. Campion, F. Kraeber-Bodere, S. Bardet, J.P. Vuillez, B. Charbonnel, V. Rohmer, C.H. Chang, R.M. Sharkey, D.M. Goldenberg, J. Barbet; French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 24(11): 1705-11, 2006.
11 W.J. McBride, P. Zanzonico, R.M. Sharkey, C. Noren, H. Karacay, E.A. Rossi, M.J. Losman, P.Y. Brard, C-H. Chang, S.M. Larson, D.M. Goldenberg. Bispecific antibody pretargeting PET (ImmunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 47(10): 1678-88, 2006.
12 D.M. Goldenberg, R.M. Sharkey, G. Paganelli, J. Barbet, J.F. Chatal. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 24(5): 823-34, 2006.

For any further information on the above-mentioned articles and papers send an email to info@immunomedics.com .